GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Moderna MRNA · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

S&P 500Nasdaq-100

Compare

199.33

+1.29%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Moderna — daily MRNA Delayed
Market value
$79.09bn
Last close × shares
Volume
8.2m
Shares, 19 Nov 2026

About Moderna

From its filings with the US Securities and Exchange Commission

SEC filings

Moderna is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MRNA. It is a member of the S&P 500 and Nasdaq-100. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $1.94bn and a net loss of $2.82bn. At that date it held total assets of $12.34bn and shareholders' equity of $8.65bn. By region, United States accounted for 61.7%, followed by Rest of world at 35.6% and Europe at 2.7%.

In its own words

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.

With a global team and a unique culture, driven by our values and mindsets, our mission is to deliver the greatest possible impact to people through mRNA medicines.

We currently have three commercial products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory syncytial virus (RSV)). mNEXSPIKE, which we launched commercially in the third quarter of 2025, is now our leading product in the U.S. retail channel. In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.

Beyond our commercial products, we continue to demonstrate the potential of our platform technology and are advancing a pipeline of development candidates across oncology, rare disease and infectious disease. In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157), our mRNA-based individualized neoantigen therapy, in combination with Merck’s pembrolizumab (KEYTRUDA®), which demonstrated sustained improvement in recurrence-free survival in patients with high-risk melanoma (stage III/IV) following complete resection.

Quoted from its 10-K, filed 20 Feb 2026. Read the filing on SEC.gov ↗

More about Moderna →

How it makes its money

Revenue, year to 31 Dec 2025

  • Net product sales $1.82bn · 93.5%
  • COVID $1.81bn · 93.1%
  • Other revenue $126.0m · 6.5%
  • Stand-ready manufacturing revenue $80.0m · 4.1%

Latest on Moderna

Our reporting

Next results

12 Feb 2027

Due on 12 Feb 2027. Analysts expect earnings of -2.07 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Moderna's ticker?

Moderna trades as MRNA on its US listing, under ISIN US60770K1079.

What was Moderna's last closing price?

199.33 on 19 Nov 2026. The figure is in USD and is never converted.

When does Moderna next report results?

Results are expected on 6 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.